Kailera Therapeutics, Inc.
NASDAQ:KLRABiotechnology
+$0.51 today
- Market cap
- $1.53B
- Beta
- 0.00
Volume 0.42M
Average 0.80M
KLRA Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Kailera Therapeutics, Inc.NASDAQ: KLRA
Operating Expenses · Q2 FY2026 · quarter ended Jun 2026
Operating expenses of $121.37M in Q2 FY2026
Q2 FY2026 operating expenses was $121.37M.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 158.34M USD
- Year-over-year change
- —
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 158.34M | — |
Operating Expenses vs competitors
How KLRA compares with its peers on the latest reported figures
- KLRA's FY2025 operating expenses of $158.34M is the 4th highest of the 10 companies compared; the peer median is $92.88M.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $560.02M | +163.1% | +77.5% | — | |
| LTM Jun 2026 | $250.97M | +6.0% | +32.7% | 3524.4% | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $160.33M | +76.4% | +57.4% | — |
KLRAKailera Therapeutics, Inc. | FY2025 | $158.34M | — | — | — |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $111.96M | +34.4% | +36.6% | 1085.3% |
| LTM Mar 2026 | $92.88M | -4.0% | +25.5% | — | |
| LTM Mar 2026 | $81.97M | -16.5% | +2.5% | 227697.2% | |
| LTM Mar 2026 | $65.98M | -50.3% | -1.5% | — | |
| LTM Mar 2026 | $39.88M | +59.2% | +10.1% | 108.3% | |
| LTM Mar 2026 | $14.22M | -0.8% | -29.6% | — | |
| Peer median (excluding KLRA) | $92.88M | +6.0% | +25.5% | 2304.8% | |
Competitors are the stored peer set for KLRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Revenue | 0 |
| Cost of Revenue | 0 |
| Gross Profit | 0 |
| Gross Margin | — |
| Research & Development | 109.11M |
| Selling, General & Admin | 49.23M |
| Operating Expenses | 158.34M |
| Depreciation & Amortization | 310K |
| EBITDA | (158.03M) |
| EBITDA Margin | — |
| Operating Income | (158.34M) |
| Operating Margin | — |
| Interest Income | 11.05M |
| Interest Expense | 0 |
| Other Income / Expenses | 9.39M |
| Income Before Tax | (148.96M) |
| Pre-Tax Margin | — |
| Income Tax Expense | 0 |
| Net Income | (148.96M) |
| Net Margin | — |
| EPS (Basic) | (1.26) |
| EPS (Diluted) | (1.26) |
| Weighted Avg Shares | 117.95M |
| Weighted Avg Shares (Diluted) | 117.95M |
Kailera Therapeutics, Inc.
NASDAQ:KLRA
Intrinsic Alpha fair value
Locked
Current Price
$11.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.